Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024

The global acute respiratory distress syndrome (ards) market has grown rapidly in recent years. It will grow from $1.17 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.

The global acute respiratory distress syndrome (ards) market is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.

The projected expansion of the acute respiratory distress syndrome (ARDS) market is directly linked to the increasing prevalence of pneumonia. Pneumonia, an infectious condition affecting one or both lungs, results in the accumulation of fluid or pus in the air sacs (alveoli) of the lungs. Pneumonia triggers an inflammatory response within the lungs, leading to heightened blood vessel permeability and the leakage of fluid into the alveoli. This accumulation of fluid disrupts the exchange of oxygen and carbon dioxide, causing respiratory distress. To illustrate, data from the Centers for Disease Control and Prevention in 2021 revealed that pneumonia accounted for 41,309 deaths in the United States, with a mortality rate of 12.4 deaths per 100,000 population. Thus, the escalating prevalence of pneumonia serves as a driving force for the growth of the acute respiratory distress syndrome (ARDS) market.

The upward trajectory in the number of respiratory illnesses is poised to contribute significantly to the expansion of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of medical conditions affecting the respiratory system, including the airways and lungs, often resulting in breathing difficulties. Notably, the surge in respiratory illnesses, exemplified by cases like COVID-19, stands out as a primary catalyst for the growth of the ARDS market. As the prevalence of respiratory illnesses continues to rise, there is a corresponding surge in demand for ARDS treatments and therapies, consequently fostering market growth. As a case in point, a March 2021 report from the Ministry of Health in Chile highlighted that respiratory diseases account for a significant percentage of mortality in Chile, constituting 47% of influenza and pneumonia cases, 3% of chronic lower respiratory tract disorders, and 3% of interstitial respiratory diseases. Additionally, other respiratory ailments make up 5% of all cases. Consequently, the mounting incidence of respiratory illnesses is a driving force behind the growth of the acute respiratory distress syndrome (ARDS) market.

The growth of the acute respiratory distress syndrome (ARDS) market is anticipated to face obstacles due to the considerable expense associated with treatment. The cost of ARDS treatment can be prohibitive, potentially limiting its accessibility to certain patients. This cost encompasses inpatient expenditures, daily ICU costs, and post-hospitalization expenses. As an illustration, in March 2022, the National Library of Medicine reported that mean inpatient ARDS costs in the United States varied from $8,476 to $547,974. Consequently, the elevated cost of treatment serves as a deterrent to the expansion of the acute respiratory distress syndrome (ARDS) market.

Prominent companies operating within the acute respiratory distress syndrome (ARDS) market are dedicating their efforts to the creation of groundbreaking drugs and supplements, including Aviptadil and HSP90 inhibitors, aimed at reinforcing their market position. Aviptadil, a synthetic vasoactive intestinal peptide (VIP), is designed to specifically target receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian pharmaceutical manufacturing company, introduced Aviptadil as a treatment for acute respiratory distress syndrome. Aviptadil, functioning as a vasoactive intestinal peptide supplement, enhances breathing and reduces mortality in ARDS patients. This is achieved through Aviptadil's capacity to safeguard and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis, and suppress interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).

In January 2022, AcelRx Pharmaceuticals Inc., a specialized pharmaceutical company based in the United States, acquired Lowell Therapeutics Inc. for $32.5 million. This strategic acquisition empowers AcelRx Pharmaceuticals to expand its product portfolio and solidify its standing in the pharmaceutical industry. Lowell Therapeutics Inc., also based in the U.S., is a pharmaceutical company dedicated to developing products for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).

Major players in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2023. The regions covered in acute respiratory distress syndrome (ARDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acute respiratory distress syndrome (ARDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The key facets of dealing with Acute Respiratory Distress Syndrome (ARDS) pertain to its diagnosis and treatment. Diagnosis encompasses the process of distinguishing this condition from other potential disorders and delineating its characteristics. The diagnosis of ARDS typically relies on a physical examination, chest X-ray, and oxygenation levels. ARDS can be triggered by various factors such as COVID-19 (COVID-19 Disease 2019), sepsis, exposure to harmful substances, severe pneumonia, among others, with its severity ranging from mild to moderate and severe. The primary recipients of ARDS-related services include hospitals, clinics, ambulatory service centers, and other healthcare facilities.

This report provides acute respiratory distress syndrome (ARDS) market statistics, including acute respiratory distress syndrome (ARDS) industry global market size, regional shares, competitors with an acute respiratory distress syndrome (ARDS) market share, detailed acute respiratory distress syndrome (ARDS) market segments, market trends and opportunities and any further data you may need to thrive in the acute respiratory distress syndrome (ARDS) industry. This acute respiratory distress syndrome (ARDS) market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.